spacer
home > ebr > autumn 2009 > spearheading innovation
PUBLICATIONS
European Biopharmaceutical Review

Spearheading Innovation

 

According to the latest report by the German Federal Government’s Commission of Experts for Research and Innovation, the biotechnology sector in Germany provides one of the most innovation-friendly and modern industrial sectors for the development of advanced technologies (1). Achievements made within biotechnology include the development of new therapies and drugs, the cultivation of improved crops, and the supply of industrial raw materials.

KEY FIGURES

Figures published in two surveys this year provide a precise and impressive overview of the current situation in the sector, which is mainly represented by small and medium-sized enterprises. At the time of the survey, some 500 companies with a total of around 14,500 employees were working in the biotechnology sector (2). Biotechnology is also becoming increasingly important in companies where it represents only part of the corporate activities. Ninety-two of these companies – particularly pharmaceutical companies and manufacturers of chemicals and seeds – employ more than 15,500 people in segments that are closely linked to biotechnology. As a result, a total of around 30,000 people are employed in commercial biotechnology.

Turnover in the sector increased by nine per cent in 2008, thus exceeding the €2 billion mark for the second year in a row. A large part of this growth – around 60 per cent – is due to successful suppliers (often in the diagnostics field). At the same time, investments in R&D increased slightly by 1.1 per cent. Therapeutic companies with products at the advanced pipeline stage in the clinical field were a contributing factor to the high expenditure on R&D, investing some €80 million. A turnover of around €54 million in the industrial biotechnology sector must also be taken into account (these statistics do not include information on the traditional chemical and pharmaceutical sectors).


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Dr Peter Heinrich is a co-founder of BIO Deutschland and has been Chairman of the Board since 2004. From 2003 to 2006, he served as the European Emerging Biopharmaceutical Enterprises’ (EBE) President. He is a co-founder of MediGene and was CEO of the company from 1995 to 2009. Prior to this position, he was Head of the Biochemistry Department at Wacker Chemie. He studied Biology and Chemistry at Munich University where he received a PhD in Biochemistry. He was subsequently a post-doc scientist for two years at Harvard University.
spacer
Peter Heinrich
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

CPI to showcase results from BioStreamline project developing novel biotherapeutics

CPI, a UK-based technology innovation centre and a founding member of the High Value Manufacturing Catapult, announced today that it will host an event in Darlington, UK on 26 June 2019 to disseminate the results of the £11.2M BioStreamline project to optimise the development of novel therapeutics. During the event, the project partners — Lonza Biologics, UCB Celltech, Sphere Fluidics, Horizon Discovery Group plc (Horizon), Alcyomics Ltd and CPI — will showcase the results and discuss the potential impact on overcoming some of the most significant shortcomings of the biologics supply chain.
More info >>

White Papers

The BioPharmaSpec Approach”: Mass Spectrometry Based Host Cell Protein Identification and Quantitation

BioPharmaSpec

1. Introduction As part of the development of any biopharmaceutical product, the impurities present must be examined, minimized and where possible characterized (1). These impurities fall into two broad categories: product-related impurities (derived specifically from the drug product itself) and process-related impurities (derived from material associated with the production, processing or purification of the sample). Host cell proteins (HCPs) are process-related impurities that require specific analysis due to the multitude of naturally occurring proteins expressed in the production cell line.
More info >>

 
Industry Events

The Universe of Pre-filled Syringes and Injection Devices

22-23 October 2019, The Swedish Exhibition & Congress Centre Gothia Towers Hotel

PDA’s Universe of Pre-filled Syringes and Injection Devices has become the must-attend meeting for everyone working in the field, and is now the world’s largest conference on this subject
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement